June 14, 2023
PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors, Strengthening Expertise in Oncology and Precision Medicine
PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression, is pleased to announce the addition of Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors.
June 7, 2023
PredxBio Strengthens Leadership Team with Appointment of Brad Spitz as Chief Commercial Officer
PredxBio, the leading company in Spatial Biology and Explainable AI for predicting the progression of disease has announced the appointment of Brad Spitz, MBA, as its Chief Commercial Officer. In this role, Brad will drive the company’s commercial growth strategy, lead global sales and business development efforts, and further expand PredxBio’s presence in the biopharma industry.
April 17, 2023
PredxBio is bending the survival curve for immunotherapy cancer patients with spatially intelligent biology at AACR 2023
PredxBio (formerly SpIntellx) announces that it will attend the 2023 Annual Meeting of American Association for Cancer Research in Orlando, April 15-19, Booth #974 and Poster #5445 to present their explainable AI-powered unbiased spatial analytics platform, that seamlessly integrates multimodal data to unravel the hidden circuitries of the tumor microenvironment and reveal the complex network biology of the cancer…
April 4, 2023
SpIntellx Rebrands as PredxBio to Unlock Spatial Biology Insights with Explainable AI
SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio (pronounced, “pre-dix-bio”). The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space…